In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633

Journal of Pharmacology and Experimental Therapeutics

Volumn 278, Issue 3, 1996, Pages 1356-1361

  Cohan, V L ^a   Showell, H J ^a   Fisher, D A ^a   Pazoles, C J ^a   Watson, J W ^a   Turner, C R ^a   Cheng, J B ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ATIZORAM; COMPLEMENT COMPONENT C5A; CYCLIC AMP; CYCLOHEXYLADENOSINE; ISOENZYME; LEUKOTRIENE B4; LIPOPOLYSACCHARIDE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PICLAMILAST; PROSTAGLANDIN E1; ROLIPRAM; SUPEROXIDE; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CONTROLLED STUDY; DRUG POTENTIATION; EOSINOPHIL; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; INFLAMMATION; MALE; MONOCYTE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONEUM EXUDATE; PRIORITY JOURNAL; T LYMPHOCYTE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING, COMPETITIVE; BRONCHODILATOR AGENTS; CLONING, MOLECULAR; CYCLIC AMP; EOSINOPHILS; GUINEA PIGS; HUMANS; ISOENZYMES; KINETICS; MONOCYTES; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PYRIMIDINONES; PYRROLIDINONES; RATS; RECEPTORS, PURINERGIC P1; ROLIPRAM; SUBSTRATE SPECIFICITY; SUPEROXIDES; THEOPHYLLINE;

EID: 0030438705     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. BEAVO, J.: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75: 725-748, 1995.
2. BOLGER, G., RODGERS, L. AND RIGGS, M.: Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases. Gene 149: 237-244, 1994.
3. BRUNS, R., LU, G. AND PUGSLEY, T.: Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. Mol. Pharmacol. 29: 331-346, 1986.
4. COHAN, V. AND NACLERIO, B.: LPS-induced tumor necrosis factor alpha release by isolated human monocytes is sensitive to agents that elevate intracellular levels of cyclic AMP. J. Immunol. 150: A212, 1993.
5. DENT, G., GIEMBYCZ, M., RABE, K. AND BARNES, P.: Inhibition of guinea pig eosinophil cyclic nucleotide phosphodiesterase activity and opsonized zymosan-stimulated respiratory burst of "type IV'-selective PDE inhibitors. Br. J. Pharmacol. 103: 1339-1346, 1991.
6. DUPLANTIER, A., BIGGERS, M., CHAMBERS, R., CHENG, J., COOPER, K., DAMON, D., EGGLER, J., KRAUS, K., MARFAT, A., MASAMUNE, H., PILLAR, J., SHIRLEY, J., UMLAND, J. AND WATSON, J.: Biarylcarboxylic acids and -amides: Inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J. Med. Chem. 39: 120-125, 1996.
7. DURHAM, S. AND KAY, A.: Eosinophils, bronchial hyperreactivity, and late-phase asthmatic reactions. Clin. Allergy 40: 411, 1985.
8. ELLIOT, M. AND MAIN, R.: New directions for biological therapy in rheumatoid arthritis. Int. Arch. Allergy Immunol. 104: 112-125, 1994.
9. ENGELS, P., SULLIVAN, M., MULLER, T. AND LUBBERT, H.: Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C). FEBS Lett. 358: 305-310, 1995.
10. FONTEH, A., WINKLER, J., TORPHY, T., HERAVI, J., UNDEM, B. AND CHILTON, F.: Influence of isoproterenol and phosphodiesterase inhibitors on platelet-activating factor biosynthesis in the human neutrophil. J. Immunol. 151: 339-350, 1993.
11. FRIGAS, E. AND GLEICH, G.: The eosinophil and the pathophysiology of asthma. J. Allergy Clin. Immunol. 77: 527-537, 1991.
12. GIEMBYCZ, M. AND DENT, G.: Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma. Clin. Exp. Allergy 22: 337-344, 1992.
13. GREWE, S., CHAN, S. AND HANIFIN, J.: Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: A possible mechanism for cyclic AMP-agonist hyporesponsiveness. J. Allergy Clin. Immunol. 70: 452-457, 1982.
14. HANIFAN, J., CHAN, S., CHENG, J., TOFTE, S., HENDERSON, W., KIRBY, D. AND WEINER, E.: In vitro and in vivo anti-inflammatory effects of type IV phosphodiesterase inhibitors in atopic dermatitis. J. Invest. Dermatol. 1996, in press.
15. HARVATH, L, MCCALL, C., BASS, D. AND MCPHAIL, L.: Inhibition of human neutrophil chemotaxis by the protein kinase inhibitor, 1-(5-isoquinolinesulfonyl)piperazine. J. Immunol. 139: 3055-3061, 1987.
16. LIVI, G., KMETZ, P., MCHALE, M., CIESLINSKI, L., SATHE, G., TAYLOR, D., DAVIS, R., TORPHY, T. AND BALCAREK, J.: Cloning and expression of cDNA for human low-Km, rolipram-sensitive cyclic AMP phosphodiesterase. Mol. Cell. Biol. 10: 2678-2686, 1990.
17. MOLNAR-KIMBAR, K., YONNO, L, HEASLIP, R. AND WICHMAN, B.: Differential regulation of TNFa and IL-1β production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors. Mediat. Inflam. 1: 411, 1992.
18. MOLNAR-KIMBER, K., YONNO, L., HEASLIP, R. AND WEICHMAN, B.: Modulation of TNF alpha and IL-1 beta endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions 39: pC77-79, 1993.
19. NICHOLSON, C., CHALLISS, R. AND SHAHID, M.: Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol. Sci. 12: 19-27, 1991.
20. PEACHELL, P., UNDEM, B., SCHLEIMER, R., MACGLASHAN, D., LICHTENSTEIN, L., CIESLINSKI, L. AND TORPHY, T.: Preliminary identification and role of phosphodiesterase isozymes in human basophils. J. Immunol. 148: 2503-2510, 1992.
21. PILLAI, R., KYTLE, K., REYES, A. AND COLICELLI, J.: Use of a yeast expression system for the isolation and analysis of drug resistant mutants of a mammalian phosphodiesterase. Proc. Natl. Acad. Sci. U.S.A. 90: 11970-11974, 1993.
22. PRABHAKAR, U., LIPSHUTZ, D., BARTUS, J., SLIVJAK, M., SMITT, I., EF, LEE, J. AND ESSER, K.: Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmacol. 16: 805-816, 1994.
23. REEVES, M., LEIGH, B. AND ENGLAND, P.: The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Biochem. J. 241: 535, 1987.
24. ROBICSEK, S., BLANCHARD, D., DJEU, J., KRZANOWSKI, J., SZENTIVANYI, A. AND POLSON, J.: Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem. Pharmacol. 42: 869-877, 1991.
25. SCHADE, U. AND SCHUDT, C.: The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur. J. Pharmacol. 230: 9-14, 1993.
26. SCHADE, V.: Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ. Shock 31: 171, 1990.
27. SEMMLER, J. H., WACHTEL, H. AND ENDRES, S.: The specific type IV phosphodiesterase inhibitor rolipram suppresses TNFa production by human mononuclear cells. Int. J. Immunopharmacol. 15: 409-413, 1993.
28. SOUNESS, J., CARTER, C., DIOCEE, B., HASSALL, G., WOOD, L. AND TURNER, N.: Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating Superoxide generation. Biochem. Pharmacol. 42: 937-945, 1991.
29. SOUNESS, J., MASLEN, C., WEBBER, S., FOSTER, M., RAEBURN, D., PALFREYMAN, M., ASHTON, M. AND KARLSSON, J.-A.: Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: Comparison with rolipram. Br. J. Pharmacol. 115: 39-46, 1995.
30. SPLENGER, R., SPLENGER, M., LINCOLN, P., REMICK, D., STRITER, R. AND KUNKEL, S.: Dynamics of dibutyryl cAMP and prostaglandin E2-mediated suppression of lipopolysacharide-induced tumor necrosis factor alpha gene expression. Infect. Immun. 57: 2837-2841, 1989.
31. STRIETER, R., REMICK, D., WARD, P., SPENGLER, R., LYNCH, J., LARRICK, J. AND KUNKEL, S.: Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem. Biophys. Res. Commun. 155: 1230-1236, 1988.
32. TORPHY, T., BARNETTE, M., HAY, D. AND UNDERWOOD, D.: Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma. Environ. Health Perspect. 102: 79-84, 1995.
33. TORPHY, T., LIVI, G. AND CHRISTENSEN, S.: Novel phosphodiesterase inhibitors for the therapy of asthma. Drug News Perspect. 6: 203-214, 1993.
34. TORPHY, T. AND UNDEM, B.: Phosphodiesterase inhibitors: New opportunities for the treatment of asthma. Thorax 46: 512-523, 1991.
35. TRACEY, K., BEUTLER, B., LOWRY, S., MERRYWHEATHER, J., WOLPE, S., MILSARK, I., HARIR, R., FAHEY III, T., ALBER, J., SHIRES, G. AND CERAMI, A.: Shock and tissue injury induced by recombinant human cachectin. Science 234: 470-474, 1986.
36. WEIGHT, C., KUIPERS, P., KOBYLARZ-SINGER, D., DEVALL, L, KLINKEFUNS, B. AND WEISHAR, R.: Differential inhibition of human neutrophil functions. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase. Biochem. Pharmacol. 40: 699-707, 1990.
37. ZABEL, P., SCHONHARTING, M., WOLTER, D. AND SCHADE, U.: Oxypentifylline in endotoxemia. Lancet 2: 1474-1477, 1989.